Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;104(19):8231-8242.
doi: 10.1007/s00253-020-10802-w. Epub 2020 Aug 20.

The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them

Pei-Yang Hu #  1 , Xiao-Ming Fan #  2 , You-Ni Zhang  1   3   4 , Shi-Bing Wang  3   4 , Wei-Jie Wan  5 , Hong-Ying Pan  6 , Xiao-Zhou Mou  7   8
Affiliations
Review

The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them

Pei-Yang Hu et al. Appl Microbiol Biotechnol. 2020 Oct.

Erratum in

Abstract

Oncolytic virus (OV) immunotherapy is characterized by viruses which specifically target cancer cells and cause their cytolysis. They provide a unique and promising new tool for the eradication of cancer as they interact with and affect the tumor microenvironment (TME), vasculature, and immune system. Advancements of genetic engineering have allowed for these viruses to be armed in such a way to have enhanced targeting, strong immunomodulation properties, and an ability to modify the TME. However, there are still major limitations in their use, mostly due to difficulties in delivering the viral particles to the tumors and in ensuring that the immunomodulatory properties are able to stimulate the host immune response to mount a complete response. Using novel delivery systems and using OVs as a complementary therapy in a combinatorial treatment have shown some significant successes. In this review, we discuss the major issues and difficulties in using OVs as anti-tumor agents and some of the strategies put in place so far to overcome these limitations. KEY POINTS: • Oncolytic viruses (OVs) infect cancer cells and cause their cytolysis. • The major limitations in using OVs as anti-tumor therapy were discussed. • The potential strategies to overcome these limitations were summarized.

Keywords: Cancer; Immunotherapy; Oncolytic virus; Oncolytic virus delivery systems; Viral-mediated anti-tumor response.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alberts P, Olmane E, Brokane L, Krastina Z, Romanovska M, Kupcs K, Isajevs S, Proboka G, Erdmanis R, Nazarovs J, Venskus D (2016) Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. Acta Pathol Microbiol Immunol Scand 124(10):896–904. https://doi.org/10.1111/apm.12576 - DOI
    1. Bai Y, Hui P, Du X, Su X (2019) Updates to the antitumor mechanism of oncolytic virus. Thorac Cancer 10(5):1031–1035. https://doi.org/10.1111/1759-7714.13043 - DOI - PubMed - PMC
    1. Banaszynski LA, Sellmyer MA, Contag CH, Wandless TJ, Thorne SH (2008) Chemical control of protein stability and function in living mice. Nat Med 14(10):1123–1127. https://doi.org/10.1038/nm.1754 - DOI - PubMed - PMC
    1. Cerullo V, Diaconu I, Romano V, Hirvinen M, Ugolini M, Escutenaire S, Holm SL, Kipar A, Kanerva A, Hemminki A (2012) An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther 20(11):2076–2086. https://doi.org/10.1038/mt.2012.137 - DOI - PubMed - PMC
    1. Chaurasiya S, Chen NG, Warner SG (2018) Oncolytic virotherapy versus cancer stem cells: a review of approaches and mechanisms. Cancers 10(4):124. https://doi.org/10.3390/cancers10040124 - DOI - PMC

LinkOut - more resources